Stockreport

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Immunopharma, Inc.  (LYEL) 
PDF Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal dev [Read more]